Certara Launches DIDB® Concomitant Meds Navigator, Extending Leadership in Drug Interaction Science
Meet DIDB Concomitant Meds Navigator—an evidence-based tool to identify contraindicated or monitored co-medications and manage…
Certara2025年9月22日
Drug Interaction Database (DIDB ®)
Optimize DDI knowledge throughout drug development
Certara2025年9月19日
Certara Launches Libra™: AI-Powered Drug-Induced Liver Injury Prediction Tool
RADNOR, Pa. – 2025年9月17日 – Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT) はCERT), a global leader in…
Certara2025年9月17日
Replacing Traditional TQT Studies with Model-Based Concentration-QTc (C-QTc) Analysis for Cardiovascular Safety in Drug Development
Learn how our experts use concentration-QTc (C-QTc) analysis to replace costly TQT studies, streamline QT…
Certara2025年8月6日
De-risking DDI Management during Clinical Trials: Introducing DIDB’s Concomitant Meds Navigator
Watch the on-demand presentation covering how the DIDB® Concomitant Meds Navigator empowers clinical development teams…
Certara2025年8月5日
Certara Simcyp® Simulator Becomes First and Only Software Platform to Receive EMA Qualification Opinion for PBPK Modeling
Certara announces that EMA has formally qualified the Simcyp® Simulator for use in regulatory submissions…
Certara2025年8月4日
What are the most common in vitro drug-drug interaction study gaps?
Certara drug interaction science experts share data and experimental design gaps commonly found in in…
Certara2025年6月9日
Clinical and Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib Drug–Drug Interactions
Director, Clinical Pharmacology, ORIC Pharmaceuticals SVP, Head of Simcyp PBPK Modeling Services, Certara Director, PBPK…
Certara2025年4月21日
